RT @Jortizsaracho: Estudios prometedores en el manejo de exacerbaciones en #COPD. Mepolizumab for Eosinophil-Associated COPD: Analysi…
Estudios prometedores en el manejo de exacerbaciones en #COPD. Mepolizumab for Eosinophil-Associated COPD: Analysis of METREX and METREO - PubMed https://t.co/7511p8Ju8q
RT @ATS_BSHSR: #Mepolizumab for #Eosinophil- #Associated #COPD: Analysis of #METREX and #METREO #Pulmonary #Lung https://t.co/YkL7mxWcy5 ht…
RT @ATS_BSHSR: #Mepolizumab for #Eosinophil- #Associated #COPD: Analysis of #METREX and #METREO #Pulmonary #Lung https://t.co/YkL7mxWcy5 ht…
RT @ATS_BSHSR: #Mepolizumab for #Eosinophil- #Associated #COPD: Analysis of #METREX and #METREO #Pulmonary #Lung https://t.co/YkL7mxWcy5 ht…
RT @ATS_BSHSR: #Mepolizumab for #Eosinophil- #Associated #COPD: Analysis of #METREX and #METREO #Pulmonary #Lung https://t.co/YkL7mxWcy5 ht…
#Mepolizumab for #Eosinophil- #Associated #COPD: Analysis of #METREX and #METREO #Pulmonary #Lung https://t.co/YkL7mxWcy5 https://t.co/VnCbUPyc8U
#Biologic drugs are changing the way we approach care. They have already started to make big waves in #astham and a recent study that we supported shows they have a place in #COPD treatment. Dove Medical Press https://t.co/VDD7n2rkU6